Well, I'm back to my old bad habits, and only posting about the Port. I do have a writeup from the Dendreon conference call last night, that I will post tomorrow.
Portfolio 24
300 Dendreon and 1000 RMTI were called away from me last Friday. I bought 4000 GNVC today, at $2.42. Cash on hand now $10,058, and the Port is worth 125,144.
I am now as excited about GenVec as I was about Dendreon. In my real life IRA, I am about 50/50 in these two, with just a few others in small amounts. Both will have large events in the next 5 to 9 weeks.
GNVC may not, and probably will not, have a statistically significant result from the upcoming interim look. However, it should let us see how it will pan out. Having an entry even here in the $2s will look really good in 2 years, if you have that kind of a time horizon. I'm going to go out on a limb here and say that before results are announced, we'll see $3.25 or $3.50 in this stock, giving you a 33 to 50% return in a month. I bought 1000 shares in my Roth today, in fact, at $2.41, with such an aim in mind.
Regards,
Trond
Showing posts with label Rockwell Medical. Show all posts
Showing posts with label Rockwell Medical. Show all posts
Tuesday, February 23, 2010
Tuesday, January 19, 2010
Port 24 and assorted biotech news
Port 24 update:
The only January options I had sold were 10 MELA $10 calls, and they were exercised, with the stock at $11.05 last Friday.
With that cash, I bought 300 more Dendreon shares today, and sold 3 Feb $32 calls against them for $0.89 per share.
I am living by my resolution to be a little more active in the Port! I also sold the following calls today:
16 ELN March $9s for $0.30
15 SGMO Feb $7.50s for $0.25
10 MELA Feb $12.50s for $0.20
2 AMAG Feb $55s for $0.50
I almost sold calls against ALTH - but I feel there is a little more room beneath the stock before selling calls. AOB needs to climb closer to $5 to make it worth selling calls, and NBIX at $2.50 is not satisfactory to sell the $2.50s, and the $5s are not worth anything yet.
The Port 24 thus has the following stocks (covered calls in parentheses)
1500 ALTH
200 AMAG (2)
2000 AOB
4900 ARNA (24)
700 DNDN (3)
1600 ELN (16)
1000 MELA (10)
2000 NBIX
2000 PGNX (20)
1000 RMTI (10)
2500 SGMO (15)
.. with cash of $2,680. This gives me a port value of about $132,500 and a 19.3% annualized return. I'm getting closer to my 24% return, again!
Stocks:
Genvec released a PR that they have licensed their hearing loss pre-clinical work to Novartis, for $5M plus milestones and royalties. They also hit the 184 death interim trigger in the PACT trial on Friday, and will have data in 10 to 12 weeks. I'm nearly as excited about Genvec as I was about Dendreon, but caution that the risk/reward is much slighter here at $2 than at $0.76 when I first mentioned it here a few months ago. I was still buying in my real-world IRA at $1.70, but am probably done for now.
Dendreon had an interview published in the Xconomy online magazine with the new COO Hans Bishop. It is a MUST READ, here: http://www.xconomy.com/seattle/2010/01/19/dendreons-new-operations-man-hans-bishop-aims-to-keep-provenge-trains-running-on-time/
Sangamo had good results (albeit from one patient, in a Phase I trial) here: http://finance.yahoo.com/news/Sangamo-BioSciences-Announces-prnews-1693198508.html?x=0&.v=1
Regards,
Trond
The only January options I had sold were 10 MELA $10 calls, and they were exercised, with the stock at $11.05 last Friday.
With that cash, I bought 300 more Dendreon shares today, and sold 3 Feb $32 calls against them for $0.89 per share.
I am living by my resolution to be a little more active in the Port! I also sold the following calls today:
16 ELN March $9s for $0.30
15 SGMO Feb $7.50s for $0.25
10 MELA Feb $12.50s for $0.20
2 AMAG Feb $55s for $0.50
I almost sold calls against ALTH - but I feel there is a little more room beneath the stock before selling calls. AOB needs to climb closer to $5 to make it worth selling calls, and NBIX at $2.50 is not satisfactory to sell the $2.50s, and the $5s are not worth anything yet.
The Port 24 thus has the following stocks (covered calls in parentheses)
1500 ALTH
200 AMAG (2)
2000 AOB
4900 ARNA (24)
700 DNDN (3)
1600 ELN (16)
1000 MELA (10)
2000 NBIX
2000 PGNX (20)
1000 RMTI (10)
2500 SGMO (15)
.. with cash of $2,680. This gives me a port value of about $132,500 and a 19.3% annualized return. I'm getting closer to my 24% return, again!
Stocks:
Genvec released a PR that they have licensed their hearing loss pre-clinical work to Novartis, for $5M plus milestones and royalties. They also hit the 184 death interim trigger in the PACT trial on Friday, and will have data in 10 to 12 weeks. I'm nearly as excited about Genvec as I was about Dendreon, but caution that the risk/reward is much slighter here at $2 than at $0.76 when I first mentioned it here a few months ago. I was still buying in my real-world IRA at $1.70, but am probably done for now.
Dendreon had an interview published in the Xconomy online magazine with the new COO Hans Bishop. It is a MUST READ, here: http://www.xconomy.com/seattle/2010/01/19/dendreons-new-operations-man-hans-bishop-aims-to-keep-provenge-trains-running-on-time/
Sangamo had good results (albeit from one patient, in a Phase I trial) here: http://finance.yahoo.com/news/Sangamo-BioSciences-Announces-prnews-1693198508.html?x=0&.v=1
Regards,
Trond
Thursday, January 7, 2010
Port 24 update, Dendreon, and GenVec
I neglected to mention yesterday that I bought 1000 shares of Rockwell Medical Technologies (RMTI) at $7.73 in the Port24. I turned and sold February $7.50 calls for $0.85 each.
I wanted to clarify in my end-of-year post that although my annualized rate of return in the Port24 is only 13%, the gross return was about 25% - we've gone from $100,000 to $125K in 19 months. I took the time to see what benchmarks might be like: the S&P in the same time frame had a -10.5% annualized return (including dividends) and the Nasdaq was 8.1%.
GenVec and Dendreon both received an opening nod and a "buy" recommendation from Roth Capital Partners this morning. Further upgrades will probably be coming shortly.
GenVec in particular is nice to see at $1.60+ this morning as it officially constitutes a double from my initial rec back in October ($0.76 was my first buy in my real-world IRA). For the record, I was still buying yesterday at $1.37. With the rise and my further buys, it is now actually my second largest holding (after Dendreon) and at this rate might be the largest in a couple days... :-)
Regards,
Trond
I wanted to clarify in my end-of-year post that although my annualized rate of return in the Port24 is only 13%, the gross return was about 25% - we've gone from $100,000 to $125K in 19 months. I took the time to see what benchmarks might be like: the S&P in the same time frame had a -10.5% annualized return (including dividends) and the Nasdaq was 8.1%.
GenVec and Dendreon both received an opening nod and a "buy" recommendation from Roth Capital Partners this morning. Further upgrades will probably be coming shortly.
GenVec in particular is nice to see at $1.60+ this morning as it officially constitutes a double from my initial rec back in October ($0.76 was my first buy in my real-world IRA). For the record, I was still buying yesterday at $1.37. With the rise and my further buys, it is now actually my second largest holding (after Dendreon) and at this rate might be the largest in a couple days... :-)
Regards,
Trond
Subscribe to:
Posts (Atom)
